These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 20406194)
1. New medical strategies for midgut carcinoids. Nilsson O; Arvidsson Y; Johanson V; Forssell-Aronsson E; Ahlman H Anticancer Agents Med Chem; 2010 Mar; 10(3):250-69. PubMed ID: 20406194 [TBL] [Abstract][Full Text] [Related]
2. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822 [TBL] [Abstract][Full Text] [Related]
3. [Drug therapy of carcinoids of the gastrointestinal tract]. Engelbach M; Heusel CP; Kriegsmann J; Both S; Walgenbach S Zentralbl Chir; 2001 Sep; 126(9):682-5. PubMed ID: 11699283 [TBL] [Abstract][Full Text] [Related]
4. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. Oberg K; Eriksson B Best Pract Res Clin Endocrinol Metab; 2005 Jun; 19(2):265-76. PubMed ID: 15763700 [TBL] [Abstract][Full Text] [Related]
5. Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study. Pivonello C; Rousaki P; Negri M; Sarnataro M; Napolitano M; Marino FZ; Patalano R; De Martino MC; Sciammarella C; Faggiano A; Rocco G; Franco R; Kaltsas GA; Colao A; Pivonello R Endocrine; 2017 Jun; 56(3):603-620. PubMed ID: 27688013 [TBL] [Abstract][Full Text] [Related]
6. Medical treatment of neuroendocrine tumours. Weber HC Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):27-31. PubMed ID: 23221494 [TBL] [Abstract][Full Text] [Related]
7. Systemic treatment of neuroendocrine tumors with hepatic metastases. Demirkan BH; Eriksson B Turk J Gastroenterol; 2012; 23(5):427-37. PubMed ID: 23161287 [TBL] [Abstract][Full Text] [Related]
8. Medical treatment of metastasizing carcinoid tumors. Arnold R World J Surg; 1996 Feb; 20(2):203-7. PubMed ID: 8661818 [TBL] [Abstract][Full Text] [Related]
9. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Modlin IM; Pavel M; Kidd M; Gustafsson BI Aliment Pharmacol Ther; 2010 Jan; 31(2):169-88. PubMed ID: 19845567 [TBL] [Abstract][Full Text] [Related]
10. [Effective treatment of a hormonally inactive carcinoid tumour with somatostatin analogues: application of serum chromogranin-A for clinical follow-up]. Igaz P; Rácz K; Tulassay Z Orv Hetil; 2007 Dec; 148(49):2343-6. PubMed ID: 18048114 [TBL] [Abstract][Full Text] [Related]
11. Molecular target therapy for gastroenteropancreatic endocrine tumours: biological rationale and clinical perspectives. Capurso G; Fazio N; Festa S; Panzuto F; De Braud F; Delle Fave G Crit Rev Oncol Hematol; 2009 Nov; 72(2):110-24. PubMed ID: 19249226 [TBL] [Abstract][Full Text] [Related]
12. [Carcinoid tumors]. Tóth M; Prónai L; Németh AM; Tulassay Z Orv Hetil; 2002 May; 143(19 Suppl):1087-92. PubMed ID: 12063867 [TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Croom KF; Perry CM Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228 [TBL] [Abstract][Full Text] [Related]
14. [Treatment of gastrointestinal neuroendocrine tumors with the somatostatin analog octreotide (Sandostatin)]. Stöckmann F; Creutzfeldt W Z Gastroenterol; 1988 Oct; 26(10):665-75. PubMed ID: 2849248 [TBL] [Abstract][Full Text] [Related]